Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 95, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/jmv.28143
Keywords
coronavirus; COVID-19; EK1; fusion inhibitor; heptad repeat 1; lipopeptide
Categories
Ask authors/readers for more resources
This review summarizes the recent development of pan-coronavirus fusion inhibitors targeting SARS-CoV-2 and its variants, highlighting their potential application in combating COVID-19 infection, reinfection, and future emerging coronavirus infectious diseases.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the currently ongoing coronavirus disease 2019 (COVID-19) pandemic, has posed a serious threat to global public health. Recently, several SARS-CoV-2 variants of concern (VOCs) have emerged and caused numerous cases of reinfection in convalescent COVID-19 patients, as well as breakthrough infections in vaccinated individuals. This calls for the development of broad-spectrum antiviral drugs to combat SARS-CoV-2 and its VOCs. Pan-coronavirus fusion inhibitors, targeting the conserved heptad repeat 1 (HR1) in spike protein S2 subunit, can broadly and potently inhibit infection of SARS-CoV-2 and its variants, as well as other human coronaviruses. In this review, we summarized the most recent development of pan-coronavirus fusion inhibitors, such as EK1, EK1C4, and EKL1C, and highlighted their potential application in combating current COVID-19 infection and reinfection, as well as future emerging coronavirus infectious diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available